Use of the Leksell gamma knife in the treatment of prolactinoma patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F09%3A3746" target="_blank" >RIV/00216208:11110/09:3746 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/67985807:_____/09:00337772 RIV/00064165:_____/09:3746

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Use of the Leksell gamma knife in the treatment of prolactinoma patients

Popis výsledku v původním jazyce

We describe our 12-year experience in treating prolactinomas with the Leksell gamma knife (LGK). We followed 35 prolactinoma patients (25.7% microprolactinomas, 74.3% macroprolactinomas) treated with LGK irradiation. The mean follow-up period was 75.5 months. Prior to LGK irradiation, patients were treated with DA and 10 of them (28.6%) underwent neurosurgery. Indications for LGK irradiation were: DA intolerance (31.4%), DA resistance (45.7%) and efforts to reduce the DA dose or shorten the period of administration (22.9%). Pituitary function was monitored regularly at 6-month intervals. The central radiation dose range was 40-80 Gy (median 70 Gy), and the minimal peripheral dose was 20-49 Gy (median 34 Gy). Normoprolactinaemia was achieved in 37.1% ofthe patients who discontinued DA and in 42.9% of patients who continued DA treatment after LGK irradiation. No relapse was seen in any patient. The size of adenoma decreased even in those patients in whom it was not changed by previous D

Název v anglickém jazyce

Use of the Leksell gamma knife in the treatment of prolactinoma patients

Popis výsledku anglicky

We describe our 12-year experience in treating prolactinomas with the Leksell gamma knife (LGK). We followed 35 prolactinoma patients (25.7% microprolactinomas, 74.3% macroprolactinomas) treated with LGK irradiation. The mean follow-up period was 75.5 months. Prior to LGK irradiation, patients were treated with DA and 10 of them (28.6%) underwent neurosurgery. Indications for LGK irradiation were: DA intolerance (31.4%), DA resistance (45.7%) and efforts to reduce the DA dose or shorten the period of administration (22.9%). Pituitary function was monitored regularly at 6-month intervals. The central radiation dose range was 40-80 Gy (median 70 Gy), and the minimal peripheral dose was 20-49 Gy (median 34 Gy). Normoprolactinaemia was achieved in 37.1% ofthe patients who discontinued DA and in 42.9% of patients who continued DA treatment after LGK irradiation. No relapse was seen in any patient. The size of adenoma decreased even in those patients in whom it was not changed by previous D

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2009

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical endocrinology

ISSN

0300-0664

e-ISSN

—

Svazek periodika

70

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

—

Kód UT WoS článku

000264563800012

EID výsledku v databázi Scopus

—